Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential MSC infusion to prevent GVHD after unrelated donor HSCT in severe β-thalassemia
ChiCTR2100050334Phase 2Recruiting
- Sponsor
- Army Medical University
- Start
- Aug 2021
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of mesenchymal stem cells in beta thalassemia major and graft-versus-host disease (GVHD) (2 arms), sponsored by Army Medical University. Primary endpoints: acute graft-versus-host disease, complete remission and 3 more. Started Aug 2021; status: recruiting.
02
Drugs
mesenchymal stem cells
03
Conditions
beta thalassemia majorgraft-versus-host disease (GVHD)
Beyond the preview
Go deeper on ChiCTR2100050334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050334.